{"id":"placebo-for-thalidomide","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL426123","moleculeType":"Small molecule","molecularWeight":"258.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert substances used as controls in clinical trials to establish the efficacy of an active drug by comparison. They rely on the placebo effect—psychological and physiological responses to the expectation of treatment—rather than any direct molecular mechanism. In this context, it serves as a comparator arm in a Phase 3 trial evaluating thalidomide or a thalidomide analog.","oneSentence":"A placebo control contains no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:25.457Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trial (indication under investigation for thalidomide comparator)"}]},"trialDetails":[{"nctId":"NCT07338344","phase":"PHASE2","title":"Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients","status":"RECRUITING","sponsor":"Rongrong Liu","startDate":"2026-02-01","conditions":"Transfusion-dependent β-thalassemia Patients","enrollment":78},{"nctId":"NCT03910244","phase":"PHASE2","title":"Pomalidomide for the Treatment of Bleeding in HHT","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2019-10-17","conditions":"Telangiectasia, Hereditary Hemorrhagic","enrollment":145},{"nctId":"NCT01283997","phase":"PHASE2","title":"Prevention of Treatment Induced Neuropathy in Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-01-25","conditions":"Myeloma","enrollment":79},{"nctId":"NCT06276933","phase":"PHASE4","title":"A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"Tongji University","startDate":"2024-02-22","conditions":"Lung Cancer, Camrelizumab","enrollment":104},{"nctId":"NCT02707484","phase":"PHASE3","title":"the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-04","conditions":"Gastrointestinal Vascular Malformation","enrollment":150},{"nctId":"NCT04273581","phase":"PHASE2","title":"The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-02-18","conditions":"COVID-19 Thalidomide","enrollment":40},{"nctId":"NCT04273529","phase":"PHASE2","title":"The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-02-20","conditions":"COVID-19 Thalidomide","enrollment":100},{"nctId":"NCT00004635","phase":"PHASE3","title":"Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-03-01","conditions":"Prostate Cancer","enrollment":159},{"nctId":"NCT00529633","phase":"PHASE3","title":"The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients","status":"TERMINATED","sponsor":"George A. Kaysen, M.D.","startDate":"2007-09","conditions":"Hypoalbuminemia","enrollment":16},{"nctId":"NCT00600028","phase":"PHASE3","title":"Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2007-12","conditions":"Idiopathic Pulmonary Fibrosis, Cough","enrollment":25},{"nctId":"NCT01858571","phase":"PHASE3","title":"Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2013-10","conditions":"Malignant Childhood Neoplasm","enrollment":108},{"nctId":"NCT02956538","phase":"EARLY_PHASE1","title":"Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2016-10","conditions":"Crohn Disease","enrollment":72},{"nctId":"NCT02203253","phase":"PHASE3","title":"Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting","status":"COMPLETED","sponsor":"China Medical University, China","startDate":"2014-07","conditions":"Neoplasms","enrollment":642},{"nctId":"NCT02754960","phase":"PHASE2","title":"Efficacy Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding","status":"WITHDRAWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2010-03","conditions":"Gastrointestinal Hemorrhage, Vascular Malformation","enrollment":""},{"nctId":"NCT02301949","phase":"PHASE2","title":"Retreatment and Its Efficiency of Thalidomide for Vascular Malformation Patients With Failure of First Course Treatment","status":"WITHDRAWN","sponsor":"Zhizheng Ge","startDate":"2015-12","conditions":"Gastrointestinal Bleeding of Unknown Origin, Gastrointestinal Vascular Malformation, Thalidomide Efficiency","enrollment":""},{"nctId":"NCT00418132","phase":"PHASE1","title":"Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2000-08","conditions":"Scleroderma, Systemic","enrollment":30},{"nctId":"NCT00075023","phase":"PHASE2","title":"Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis","status":"TERMINATED","sponsor":"National Institute of Nursing Research (NINR)","startDate":"2003-12","conditions":"Graft-versus-Host Disease, Stomatitis","enrollment":10},{"nctId":"NCT00019747","phase":"PHASE2","title":"Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"1999-08","conditions":"Colorectal Cancer","enrollment":39},{"nctId":"NCT00057564","phase":"PHASE3","title":"A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2003-02","conditions":"Multiple Myeloma","enrollment":470},{"nctId":"NCT01914770","phase":"","title":"Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Systemic Lupus Erythematosus","enrollment":1016},{"nctId":"NCT01638078","phase":"PHASE4","title":"Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2014-01","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT00379353","phase":"PHASE2","title":"The Effects of Thalidomide on Symptom Clusters","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-09","conditions":"Advanced Cancers","enrollment":32},{"nctId":"NCT00030550","phase":"PHASE2","title":"Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2001-09","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":""},{"nctId":"NCT01094340","phase":"PHASE2, PHASE3","title":"Thalidomide for Patients With Mild to Moderate Alzheimer's Disease","status":"UNKNOWN","sponsor":"Banner Health","startDate":"2010-03","conditions":"Alzheimer's Disease","enrollment":20},{"nctId":"NCT00061919","phase":"PHASE3","title":"Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University College, London","startDate":"2003-04","conditions":"Lung Cancer","enrollment":724},{"nctId":"NCT00003894","phase":"PHASE2","title":"Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"1999-03","conditions":"Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":36},{"nctId":"NCT00053430","phase":"PHASE2","title":"Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-04","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00644306","phase":"PHASE3","title":"Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma","status":"TERMINATED","sponsor":"Central Hospital, Nancy, France","startDate":"2002-04","conditions":"Newly Diagnosed, Multiple Myeloma","enrollment":232},{"nctId":"NCT00001680","phase":"PHASE2","title":"A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1997-10","conditions":"Discoid Lupus Erythematosus","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo tablet for thalidomide"],"phase":"phase_3","status":"active","brandName":"Placebo for thalidomide","genericName":"Placebo for thalidomide","companyName":"China Medical University, China","companyId":"china-medical-university-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo control contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in Phase 3 clinical trial (indication under investigation for thalidomide comparator).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}